Safety and Efficacy of Liver-Directed Radiotherapy in Combination With Lenvatinib for Hepatocelluar Carcinoma With Macroscopic Tumor Thrombosis.

Front Oncol · 2022 · PMC9130955 · PMID 35646674

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0700

boldest claim

The sentences

marginally significantp = 0.06so close (0.05 < p ≤ 0.1)

A significant difference between the two groups was found in IHPFS (p = 0.008, hazard ratio [HR] 0.45, 95% confidence interval [CI] 0.25–0.81) and PFS (p = 0.008, HR 0.47, 95% CI 0.27 – 0.82), but only a marginally significant difference in OS (p = 0.06, HR 0.54, 95% CI 0.28 – 1.03) was observed in the univariable analysis.

also in 26,082 other papers

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Duration of Lenvatinib Treatment and Liver Function Maintenance Although there was no statistical difference in the duration of lenvatinib use between the two groups, the LRT group showed a trend toward longer treatment (p = 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.